Perfusion Abnormalities in Hypertrophic Cardiomyopathy

N/ANot Yet RecruitingNCT06599229

University of Virginia30 enrolled

Overview

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hypertrophic Cardiomyopathy (HCM)

Interventions

myocardial contrast echoDIAGNOSTIC_TEST

Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of hypertrophic cardiomyopathy * Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy Exclusion Criteria: * Pregnancy * Lactation * Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson * Serious AE to regadenoson * Hypotension * Serious bradycardia not addressed by pacemaker * Moderate or greater reactive airways disease

Outcomes

Primary Outcomes

Peak hyperemic perfusion

Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson)

Time frame: 3 months

Secondary Outcomes

Resting myocardial perfusion

Resting myocardial perfusion by MCE

Time frame: 3 months

Central Contacts

Jonathan Lindner, MD

CONTACT

4342979442 jlindner@virginia.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.